Molecular Genetics & Genomic Medicine (Feb 2023)

Characterization of a germline variant MSH6 c.4001G > C in a Lynch syndrome family

  • Ciyu Yang,
  • Maksym Misyura,
  • Sarah Kane,
  • Vikas Rai,
  • Alicia Latham,
  • Liying Zhang

DOI
https://doi.org/10.1002/mgg3.2104
Journal volume & issue
Vol. 11, no. 2
pp. n/a – n/a

Abstract

Read online

Abstract Background Germline variants in the DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6, and PMS2) cause Lynch syndrome, an autosomal dominant hereditary cancer susceptibility syndrome. The risk for endometrial cancer is significantly higher in women with MSH6 pathogenic/likely pathogenic (P/LP) variants compared with that for MLH1 or MSH2 variants. Methods The proband was tested via a clinical testing, Memorial Sloan Kettering‐Integrated Mutation Profiling of Actionable Cancer Targets (MSK‐IMPACT). RT‐PCR was performed using patient's blood DNA and cDNA was analyzed by DNA sequencing and a cloning approach. Results We report a 56‐year‐old female with endometrial cancer who carries a germline variant, MSH6 c.4001G > C, located at the last nucleotide of exon 9. While the pathogenicity of this variant was previously unknown, functional studies demonstrated that this variant completely abolished normal splicing and caused exon 9 skipping, which is expected to lead to a prematurely truncated or abnormal protein. Conclusion Our results indicate that this variant likely contributes to cancer predisposition through disruption of normal splicing, and is classified as likely pathogenic.

Keywords